Compare BKTI & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKTI | IMMX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.9M | 306.2M |
| IPO Year | 2000 | 2021 |
| Metric | BKTI | IMMX |
|---|---|---|
| Price | $83.26 | $8.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $74.00 | $19.20 |
| AVG Volume (30 Days) | 47.8K | ★ 787.6K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.89 | N/A |
| EPS | ★ 3.44 | N/A |
| Revenue | ★ $74,094,000.00 | N/A |
| Revenue This Year | $10.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.13 | ★ N/A |
| Revenue Growth | ★ 45.42 | N/A |
| 52 Week Low | $35.76 | $1.34 |
| 52 Week High | $89.50 | $11.61 |
| Indicator | BKTI | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 51.12 |
| Support Level | $73.60 | $2.20 |
| Resistance Level | $87.21 | $8.97 |
| Average True Range (ATR) | 4.25 | 1.04 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 97.33 | 25.21 |
BK Technologies Corp is a holding company that, through BK Technologies, Inc., its operating subsidiary, provides public safety-grade communications products and services designed to make first responders safer and more efficient. All operating activities described herein are undertaken by its operating subsidiary. The Company has one reportable segment - Land Mobile Radio (LMR) Products and Solutions. The LMR segment provides radio devices that are hand-held (portable) or installed in vehicles (mobile) and operate on private radio systems that are P25 compliant. The Company derives revenue in North America and manages the business activities on a consolidated basis.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.